Stocks · News reference
Filed: 2026-08-12 AccNo: 0001628280-26-055962 Size: 182 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Madrigal Pharmaceuticals announced it will present multiple abstracts, including new real-world evidence for its MASH treatment Rezdiffra, at the upcoming AASLD The Liver Meeting.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a
Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.
Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.